| Alysha Nicole Kirkwood, DO | |
|
588 E Lakewood Blvd, 2nd Floor, Holland, MI 49424-2023 | |
| (616) 494-5850 | |
| (616) 494-5901 |
| Full Name | Alysha Nicole Kirkwood |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 588 E Lakewood Blvd, Holland, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063698033 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 5101017236 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Health Saint Mary's | Grand rapids, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advantage Health/saint Mary's Medical Group | 4082807961 | 398 |
News Archive
Florida State University researchers led by physics doctoral student Campion Loong have achieved significant benchmarks in a study of the human cardiac protein alpha-tropomyosin, which is an essential, molecular-level component that controls the heart's contraction on every beat.
With its ten new Research Units, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is intensifying interdisciplinary and multiple-location collaboration among researchers pursuing specific scientific questions and new avenues of research.
Kaiser Health News writer Jenny Gold, in collaboration with NPR, examines the growing trend of doctors opting not to open a private practice but work instead for a hospital.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.
› Verified 6 days ago
| Entity Name | Mercy Health Partners - Physician Specialist |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922248772 PECOS PAC ID: 2163572991 Enrollment ID: O20090616000615 |
News Archive
Florida State University researchers led by physics doctoral student Campion Loong have achieved significant benchmarks in a study of the human cardiac protein alpha-tropomyosin, which is an essential, molecular-level component that controls the heart's contraction on every beat.
With its ten new Research Units, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is intensifying interdisciplinary and multiple-location collaboration among researchers pursuing specific scientific questions and new avenues of research.
Kaiser Health News writer Jenny Gold, in collaboration with NPR, examines the growing trend of doctors opting not to open a private practice but work instead for a hospital.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.
› Verified 6 days ago
| Entity Name | Advantage Health/saint Mary's Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376862151 PECOS PAC ID: 4082807961 Enrollment ID: O20101023000279 |
News Archive
Florida State University researchers led by physics doctoral student Campion Loong have achieved significant benchmarks in a study of the human cardiac protein alpha-tropomyosin, which is an essential, molecular-level component that controls the heart's contraction on every beat.
With its ten new Research Units, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is intensifying interdisciplinary and multiple-location collaboration among researchers pursuing specific scientific questions and new avenues of research.
Kaiser Health News writer Jenny Gold, in collaboration with NPR, examines the growing trend of doctors opting not to open a private practice but work instead for a hospital.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alysha Nicole Kirkwood, DO 100 Michigan St Ne, Mc 845, Grand Rapids, MI 49503-2560 Ph: () - | Alysha Nicole Kirkwood, DO 588 E Lakewood Blvd, 2nd Floor, Holland, MI 49424-2023 Ph: (616) 494-5850 |
News Archive
Florida State University researchers led by physics doctoral student Campion Loong have achieved significant benchmarks in a study of the human cardiac protein alpha-tropomyosin, which is an essential, molecular-level component that controls the heart's contraction on every beat.
With its ten new Research Units, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is intensifying interdisciplinary and multiple-location collaboration among researchers pursuing specific scientific questions and new avenues of research.
Kaiser Health News writer Jenny Gold, in collaboration with NPR, examines the growing trend of doctors opting not to open a private practice but work instead for a hospital.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.
› Verified 6 days ago
Mark W Lenters, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 | |
James W Gerard, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 | |
Dr. Michael Shawn Werkema, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 | |
Dr. Kristyn Dae Oswald, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 | |
Sarah E Strong, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 | |
Barbara E Puzycki, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 664 Michigan Ave, Holland, MI 49423 Phone: 616-392-5973 Fax: 616-392-1646 |